Caplin Point Laboratories Limited (CAPLIPOINT) — Announcement

1 Announcement Neutral 📄 PDF

📢 Key Event
Audio recording of Q4 earnings call made available

💡 Investor Takeaway
Investors can now listen to the full earnings discussion to assess performance and outlook.

Caplin Point Laboratories announced that the audio recording of its Q4 FY2025-26 earnings call held on May 14, 2026, is now available on its website for investors to access.

2 Announcement Neutral 📄 PDF

📢 Key Event
Caplin Steriles secures USFDA approval for Foscarnet Sodium Injection

💡 Investor Takeaway
This approval opens access to a $15 million US market and strengthens Caplin's position in high-growth sterile injectable generics.

Caplin Point Laboratories announced that its subsidiary Caplin Steriles received final USFDA approval for Foscarnet Sodium Injection, a generic antiviral treatment for CMV retinitis and HSV infections. The product targets a $15 million US market opportunity and marks the company's expansion into high-value sterile injectables for regulated markets like the US and Europe.

📊 Stock Analysis — CAPLIPOINT ✨ Ask AI About This